SCHEMBL3053121

SCHEMBL3053121

Cc1nnc(Cl)c(-c2c(F)cc(F)cc2F)c1Cc1cccc(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 2/20 0.38
ENPP1 P22413 1/20 0.38
TAAR1 Q96RJ0 2/20 0.35
ADCY10 Q96PN6 1/20 0.35
LMNA P02545 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
TP53 P04637 1/20 0.34
PNMT P11086 2/20 0.33
MAPT P10636 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
KMT2A Q03164 1/20 0.33
ALKBH3 Q96Q83 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
ADORA1 P30542 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3063123 0.90 TAAR1 (0.35) ENPP1TAAR1ADCY10SMN1; SMN2KDM4E
SCHEMBL3063211 0.86 KMT2A (0.38) ENPP1LMNAKDM4ETP53MAPT
SCHEMBL3060845 0.83 AR (0.32) LMNASMN1; SMN2HPGDMAPTMEN1
SCHEMBL3068887 0.79 SMN1; SMN2 (0.40) ENPP1TAAR1SMN1; SMN2HPGDALDH1A1
SCHEMBL3073957 0.79 HPGD (0.34) TAAR1SMN1; SMN2HPGDALDH1A1KMT2A
SCHEMBL2350675 0.76 IKBKE (0.40) SMN1; SMN2TP53MEN1KMT2A
SCHEMBL3067257 0.74 NPSR1 (0.41) TAAR1LMNASMN1; SMN2KDM4EHPGD
SCHEMBL3074091 0.73 KMT2A (0.36) ENPP1LMNASMN1; SMN2KDM4ETP53
SCHEMBL3073947 0.73 PLA2G2A (0.38) SMN1; SMN2KDM4EHPGDALDH1A1
SCHEMBL3573800 0.72 IDO1 (0.42) SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100273804-A1 PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER SYNGENTA CROP PROTECTION, INC. (US) 2010-10-28 US claimed
EP-2220051-A1 PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER Syngenta Participations AG (CH) 2010-08-25 EP claimed
WO-2009080314-A1 PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER SYNGENTA PARTICIPATIONS AG (CH) 2009-07-02 WO claimed
US-20100273804-A1 PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER SYNGENTA CROP PROTECTION, INC. (US) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273804-A1 PYRIDAZINE DERIVATIVES USEFUL AS FUNGICIDES AND FOR THE TREATMENT OF CANCER C3AR1, CBR3, C1S CCR2 342/4885ENPP1 1959/4885TAAR1 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.